COVID-19 Linked to Cognitive Decline, Potential Treatment Found in Diabetes Drug
A new study reveals the novel coronavirus significantly impacts brain function, leading to cognitive impairment, but researchers have identified a potential therapeutic avenue using a common diabetes medication. The findings, released by the Korea Disease Control and Prevention Agency’s National Institute of Health, shed light on the long-term neurological consequences of COVID-19 infection and offer a glimmer of hope for mitigating its effects.
Spike Protein Disrupts Brain Function
Research indicates the spike protein (S1) of the COVID-19 virus doesn’t just attack the respiratory system; it actively travels to the brain, disrupting crucial neurological processes. According to the study, the spike protein interferes with the connections between nerve cells and reduces the expression of genes responsible for NMDA receptor production – a critical component in memory formation. This disruption also appears to accelerate the accumulation of toxic proteins associated with neurodegenerative diseases like dementia and Parkinson’s disease.
Animal experiments provided compelling evidence of these effects. When the COVID-19 spike protein was administered to mice, researchers observed a marked decline in learning and memory capabilities, evidenced by increased difficulty navigating familiar mazes. These findings mirrored symptoms of cognitive decline reported in humans following COVID-19 infection, including heightened anxiety in unfamiliar environments.
“After six weeks of administration, a decrease in the number of neurons in the brain and accumulation of pathological proteins that occur in degenerative brain diseases were confirmed, raising the possibility of long-term brain damage,” a senior researcher stated.
Toxic Protein Buildup Confirmed
Further analysis revealed a significant increase in the levels of tau and alpha synuclein proteins in the brains of mice exposed to the virus. These proteins are hallmarks of several debilitating neurological conditions. The Korea Disease Control and Prevention Agency provided images illustrating the increased presence of these toxic proteins.
. (A graphic illustrating the accumulation of tau and alpha synuclein in the brains of infected mice would be beneficial here.)
Metformin Shows Promise in Restoring Brain Function
However, the research isn’t solely focused on the negative impacts of the virus. Scientists discovered a potential pathway to recovery through the use of metformin, a widely prescribed medication for type 2 diabetes. Experiments demonstrated that administering metformin alongside the spike protein mitigated the neurological damage, restoring nerve cell function and reducing the buildup of toxic proteins.
Dr. Ko Young-ho, leading the research team at the National Institute of Health, emphasized the significance of the findings. “It is significant that it revealed the pathological mechanism of cognitive impairment that appears after COVID-19 infection and suggested the possibility that metformin, which is widely used in clinical practice, can suppress it,” he said, adding that further clinical research is needed to fully explore metformin’s potential as a treatment for long-term COVID-19 sequelae.
Call for Continued Research
The Director of the Korea Disease Control and Prevention Agency, Lim Seung-gwan, underscored the importance of ongoing investigation into the long-term effects of COVID-19. “Research is needed on patients experiencing long-term symptoms after COVID-19,” he stated, committing to continued support for scientific studies aimed at informing public health policies.
The study represents a crucial step forward in understanding the complex neurological consequences of COVID-19 and offers a promising avenue for developing effective treatments for those grappling with its lasting effects.
